Positioning of Aminopeptidase Inhibitors in Next Generation Cancer Therapy

Sarina M Hitzerd,
Sue Ellen Verbrugge,
Gert Ossenkoppele,
Gerrit Jansen,
Godefridus J. Peters.

Amino Acids, accepted for publication

Departments of Medical Oncology, Hematology, Rheumatology VU University Medical Center, Amsterdam, The Netherlands
Aminopeptidases represent a class of (zinc) metalloenzymes that catalyze the cleavage of amino acids nearby the N-terminus of polypeptides, resulting in hydrolysis of peptide bonds. Aminopeptidases operate downstream of the ubiquitin-proteasome pathway and are implicated in the final step of intracellular protein degradation either by trimming proteasome-generated peptides for antigen presentation or full hydrolysis into free amino acids for recycling in renewed protein synthesis. This review focuses on the function and subcellular location of five key aminopeptidases (aminopeptidase N (APN), leucine aminopeptidase (LAP), puromycin-sensitive aminopeptidase (PuSA), leukotriene A₄ (LTA₄) hydrolase and endoplasmic reticulum aminopeptidase 1/2 (ERAP1/2)) and their association with different diseases, in particular cancer and their current position as target for therapeutic intervention by aminopeptidase inhibitors.

Historically, bestatin was the first prototypical aminopeptidase inhibitor that entered the clinic 35 years ago and is still used for the treatment of lung cancer. More recently, new generation aminopeptidase inhibitors became available, including the aminopeptidase inhibitor prodrug tosedostat, which is currently tested in phase II clinical trials for acute myeloid leukemia. Beyond bestatin and tosedostat, medicinal chemistry has emerged with additional series of potential aminopeptidases inhibitors which are still in an early phase of (pre)clinical investigations. The expanded knowledge of the unique mechanism of action of aminopeptidases has revived interest in aminopeptidase inhibitors for drug combination regimens in anticancer treatment. In this context, this review will discuss relevant features and mechanisms of action of aminopeptidases and will also elaborate on factors contributing to aminopeptidase inhibitor efficacy and/or loss of efficacy due to drug resistance-related phenomena. Together, a growing body of data point to aminopeptidase inhibitors as attractive tools for combination chemotherapy, hence their implementation may be a step forward in a new era of personalized treatment of cancer patients.
Introduction

More than fifty years ago, Rutenburg et al. and Willighagen and Planteydt were the first to report the potential relevance of aminopeptidase activity for cancer.\textsuperscript{1,2} Rutenburg et al. demonstrated that patients with pancreatic cancer had significantly increased leucine aminopeptidase (LAP) activity in serum and urine, whereas patients with a malignant lymphoma or leukemia had increased LAP activity in urine.\textsuperscript{1} Willighagen and Planteydt also observed higher aminopeptidase activity in tumor cells and stroma in sixty surgically removed human neoplasms.\textsuperscript{2} Twenty years later, Umezawa et al. discovered one of the first aminopeptidase inhibitors; bestatin, being produced by actinomycetes, a group of gram-positive bacteria.\textsuperscript{3}

Aminopeptidases, a class of (zinc) metalloenzymes, catalyze the cleavage of amino acids nearby the N-terminus of polypeptides, facilitating hydrolysis of the peptide bond.\textsuperscript{4} Binding of one or two metal ions, mostly zinc, is required for the activity of the aminopeptidases. Some of these enzymes require two metal ions for full activity, for others only one metal ion is sufficient for catalysis, while the second metal ion can modulate the activity either positively or negatively. Aminopeptidases are widely distributed throughout plants, animals, bacteria and fungi, and function in many cellular processes.\textsuperscript{5} Their function is implicated in the final step of intracellular protein degradation by trimming peptides produced by the ubiquitin-proteasome pathway either for antigen presentation or for full hydrolysis into free amino acids, which can be reutilized for renewed protein synthesis (Figure 1).\textsuperscript{6} The critical relevance of these functions for cancer progression paved the way to explore inhibitors of aminopeptidases for application as anti-cancer therapeutic drugs. The mechanistic rationale and current status of established and experimental aminopeptidase inhibitors for next generation cancer therapy is discussed hereafter.
1. Positioning of Aminopeptidases

1.1 Mechanism of action downstream of the ubiquitin-proteasome pathway

The ubiquitin-proteasome pathway is the major proteolytic system in the cytosol of eukaryotic cells, and plays an important role in protein homeostasis, degradation of specific short-lived proteins and rapid elimination of damaged or misfolded proteins. Intracellular ubiquitin-mediated protein degradation is highly selective; different proteins can have a half-life that varies from a few minutes to several days and up to a few years. This process is tightly regulated and has been implicated in numerous key processes such as DNA repair, cell-cycle progression, signal transduction, transcriptional regulation, receptor down-regulation, and gene expression. The ubiquitin system is also essential for immune response, development, and programmed cell death.7,8

Two main steps are involved in the degradation of a protein via the ubiquitin-proteasome pathway: 1) labeling of the protein by the covalent attachment of multiple ubiquitin (Ub) molecules and 2) degradation of the labeled protein by the 26S proteasome complex. These steps require the sequential action of three enzymes; E1 (Ub-activation), E2 (Ub-conjugation) and E3 (Ub-ligation). The short peptides, ultimately generated by the ubiquitin-proteasome processes are short-lived and do not accumulate in cells, but are further degraded to free amino acids by cytosolic peptidases, such as aminopeptidases.9–15

Aminopeptidases directly degrade the smallest products (2-6 amino acids) released from the proteasome complex, whereas larger peptides (6-24 amino acids) are primarily cleaved by endopeptidases, such as thimet oligopeptidases (TOP) and tripeptidyl peptidase II (TPPII), into shorter peptides (2-6 amino acids), which subsequently can be fully hydrolyzed by aminopeptidases (Figure 1; Complete hydrolysis) to free amino acids being available again for new protein synthesis.6,16

A very small fraction of the proteasome products can escape the complete hydrolysis and is utilized for major histocompatibility complex (MHC) class I antigen presentation (Figure 1; Antigen presentation). These peptides are transported from the cytosol into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP). Additionally, the N-terminal extension of peptides can be processed before transportation (cytosol) or after transportation (ER) by specific aminopeptidases. This
phenomenon is also called ‘trimming’.\textsuperscript{6,11,17} Subsequently, the MHC class I molecules bind the (trimmed) peptides (8-10 amino acids) and expose them on the cell surface for recognition by cytotoxic T lymphocytes and initiating an immune response.\textsuperscript{18} The role of aminopeptidase activity in antigen presentation has been subject of various reviews.\textsuperscript{19–25} This review will primarily focus on the role of aminopeptidases in the peptide hydrolysis to amino acids from a cancer perspective.

### 1.2 Function and location of different aminopeptidases and their association with different diseases

The function and subcellular location of at least five aminopeptidases (aminopeptidase N (APN), leucine aminopeptidase (LAP), puromycin-sensitive aminopeptidase (PuSA), leukotriene A\textsubscript{4} (LTA\textsubscript{4}) hydrolase and endoplasmic reticulum aminopeptidase 1/2 (ERAP1/2)) has been associated with the pathophysiology of different non-malignant diseases (discussed in this

---

*Figure. 1. Protein degradation pathway; role of proteasome and aminopeptidases.*

*Abbreviations: aa, amino acid; TOP, thimet oligopeptidases; MHC, major histocompatibility complex.*

*Modified from Saric et al.\textsuperscript{2004*55*}.*
Aminopeptidases can be subdivided into three general groups, based on their function, those that: 1) hydrolyze the first peptide bond (aminooacyl- and iminoacyl-peptide hydrolases), 2) remove dipeptides from polypeptide chains (dipeptidyl-peptide hydrolases), and 3) only act on tripeptides (tripeptidyl-peptide hydrolases). They can also be subdivided based on structural characteristics. Four of the five aminopeptidases (APN, PuSA, LTA₄ hydrolase and ERAP1/2) belong to the M1 zinc-aminopeptidases subfamily, which harbor a consensus HEXXH(18X)E motif for zinc binding. This zinc ion binding is essential for the enzymatic activity of aminopeptidases. LAP is a member of the peptidase M17 family.

1.2.1 Aminopeptidase N (APN)
Aminopeptidase N (APN, also known as CD13) has been referred to as a ‘moonlighting ectoenzyme’, because it can fulfill a multitude of functions. Upon ligand binding, APN can operate as an enzyme, a receptor and/or signaling molecule. Each of these three functions is associated with their own mechanism of action; peptide cleavage, endocytosis and signal transduction, respectively. Subsequently, each of these three mechanisms elicited different biological effects. Generally, APN plays a role in the final digestion of peptides generated from hydrolysis of proteins and polypeptides, in particular those involved in the metabolism of various regulatory peptides that impact the function of small intestinal and tubular epithelial cells, macrophages, granulocytes and synaptic membranes from the CNS. Moreover, APN can cleave antigenic peptides prior to binding to MHC class II molecules of antigen presenting cells.

1.2.2 Leucine aminopeptidase (LAP)
Unlike APN, leucine aminopeptidase (LAP, also known as cytosol aminopeptidase) is less well characterized. It catalyzes the removal of unsubstituted N-terminal amino acids from various peptides and is presumably involved in the processing and regular turnover of intracellular proteins. Subsequently, it processes antigenic peptides for presentation by the MHC class I molecules. LAP is located in the cytoplasm, but data on tissue specificity are scarce. LAP has been implicated in a small variety of pathophysiological states, including HIV
infection, systemic lupus erythematosus and malaria.\textsuperscript{32–34}

1.2.3 \textit{Puromycin-sensitive aminopeptidase (PuSA)}
Puromycin-sensitive aminopeptidase (PuSA) has broad substrate specificity for several peptides and is involved in proteolytic events essential for cell growth and viability.\textsuperscript{35} As for APN, PuSA is thought to act as a regulator of neuropeptide activity\textsuperscript{36} and plays an important role in the antigen-processing pathway for MHC class I molecules.\textsuperscript{25,37,38} PuSA is also able to digest polyglutamine (polyQ) peptides found in many cellular proteins.\textsuperscript{39} PuSA is localized in both the cytoplasm and cellular membranes, and was found in liver, epithelium of renal tubules, epithelium of small and large intestine, gastric epithelial cells, and alveoli of the lung.\textsuperscript{40} PuSA was found to be involved in the degradation of tau, which does it more efficiently in normal brain compared to brain from Alzheimer disease patients.\textsuperscript{41,42}

1.2.4 \textit{Leukotriene A\textsubscript{4} (LTA\textsubscript{4}) hydrolase}
Leukotriene A\textsubscript{4} (LTA\textsubscript{4}) hydrolase is involved in the removal of a single N-terminal amino acid residue and exhibits a variety of important biological functions, including the processing of cell surface antigens and involvement in tumor angiogenesis. LTA\textsubscript{4} hydrolysis catalyzes the formation of the chemotaxin Leukotriene B\textsubscript{4} (LTB\textsubscript{4}), a key lipid mediator of the innate immune response; it stimulates adhesion of circulating neutrophils to vascular endothelium and directs their migration to sites of inflammation.\textsuperscript{43–45} LTA\textsubscript{4} hydrolase is compartmentalized in lipid-rich organelles (lipid droplets) residing in the cytoplasm and is expressed in monocytes, lymphocytes, neutrophils, reticulocytes, platelets and fibroblasts.\textsuperscript{46–48} LTB\textsubscript{4} plays an important role in a variety of allergic and inflammatory reactions, due to these biological activities of LTB\textsubscript{4}, LTA\textsubscript{4} hydrolase is involved in a variety of acute and chronic inflammatory diseases, e.g., nephritis, arthritis, dermatitis, chronic obstructive pulmonary disease and asthma.\textsuperscript{47–51}

1.2.5 Endoplasmic reticulum aminopeptidase 1/2 (ERAP1/2)
The main function of endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1; also known as puromycin-insensitive leucine aminopeptidase (PILSAP) and
ERAP2) involves trimming of HLA class I-binding precursors in the endoplasmic reticulum (ER) for MHC class I antigen presentation. ERAP1 and 2 can act as monomer, but mostly function as heterodimers allowing them to combine their restricted specificities to remove complex N-terminal extensions. In addition, ERAP1 has a unique substrate preference; it strongly prefers peptide substrates between nine and sixteen amino acid residues long and thereby covers the formation of about one third of peptide–MHC class I complexes. ERAP2 presents distinct specificity for the N-terminal residue of the peptide substrates. Both enzymes are also thought to play a role in the inactivation of peptide hormones. ERAP1 is also found to be involved in blood pressure regulation by inactivation of angiotensin II. ERAP1 and 2 are localized on the ER membrane and are ubiquitously expressed, mostly in spleen and leukocytes.

### 1.3 Relation between aminopeptidases and cancer

Aminopeptidases are essential for physiologically important processes such as protein maturation, degradation of peptides, and cell cycle control. For cancer cells, the supply of cellular free amino acids, regulated by aminopeptidases, is of utmost importance for their survival and proliferation. Importantly, many tumor cells are dependent on specific amino acids and depletion of these amino acids has a greater impact on cancer cells than normal cells. Moore et al. indicated that myeloid leukemia and multiple myeloma cells were highly dependent on the unfolded protein response in which aminopeptidases play an important role. Consistently, this study showed that aminopeptidase inhibition resulted in marked inhibition of myeloma cell growth and survival, and thus of potential therapeutic interest. Martinez et al. documented both up- and down regulation of selective aminopeptidase activities in breast cancer tissue. These alterations were dependent on local hormonal status, indicating that tumor microenvironment plays a role in regulating aminopeptidase expression. Cifaldi et al. discussed the outcome of six different studies that assessed the expression and tissue distribution of endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1 and ERAP2) in tumor cells of lymphoid and non-lymphoid origin compared to their normal counterparts. In one study including eleven different tumor cell lines (melanomas, leukemia-lymphomas and carcinomas of breast, colon, lung, chorion, skin, prostate, cervix, kidney and bladder),
ERAP1 and ERAP2 were expressed at highly variable levels. In a second study, the expression of ERAP1 and ERAP2 was either lost, acquired or retained in 150 surgically removed neoplastic lesions as compared to their normal histotype counterparts. Down-regulation of ERAP1 and/or ERAP2 expression was mainly found in ovarian, breast and lung carcinomas, whereas an up-regulation of these enzymes was observed in colon and thyroid carcinomas. A third study reported heterogeneous expression of ERAP1 and ERAP2, ranging from high to very low levels, in 28 melanoma cell lines as compared to primary melanocytes. Three other studies demonstrated ERAP1 expression in 64% of endometrial carcinomas, in which ERAP1 may function to suppress angiogenesis and endothelial cell migration. Both ERAP1 and 2 are present in leukemia, lymphoma, carcinoma, and melanoma cell lines. 63-66 Mostly ERAP1 is involved in a few types of cancer, such as endometrial carcinoma and cervical carcinoma. 66,67 Most studies on aminopeptidase activity in correlation with cancer are focused on aminopeptidase N (APN), a zinc-dependent membrane-bound ectopeptidase that degrades preferentially proteins and peptides with a N-terminal neutral amino acid. Tokuhara et al. investigated the clinical significance of aminopeptidase N in non–small cell lung cancer (NSCLC) and were the first to show a relationship between APN expression and poor prognosis of patients with NSCLC. 68 Van Hensbergen et al. found elevated soluble APN activity in plasma and effusions of cancer patients, which was strongly correlated with tumor load. 69 APN also appeared to be involved in cell motility of thyroid carcinoma cells, 70 of which undifferentiated anaplastic thyroid carcinomas had a higher APN expression than differentiated thyroid carcinomas. Increased APN expression was associated in the pathophysiology of additional types of cancer; head and neck squamous cell carcinoma, 71 acute myeloid leukemia, prostate cancer and colon cancer. 72-75 Beyond this, APN was also found to be selectively expressed in the vasculature of tissues that undergo angiogenesis, e.g. in malignant gliomas and lymph node metastases from multiple tumor types, but not in blood vessels of normal tissues. 76 In line with these observations, APN serves as a receptor for a specific motif (NGR), which is expressed on endothelial cells of angiogenic vasculature. 77 Collectively, it can be concluded that an increased APN expression was related to a more malignant phenotype. Other than for APN and ERAP, cancer-related involvement of additional
aminopeptidases is less well documented. Notwithstanding this fact, leucine aminopeptidase (LAP) activity appeared to play a role in prostate carcinoma and head and neck cancer; PuSA activity in clear cell renal cancer and prostate adenocarcinoma, and LTA₄ hydrolase in lung cancer, esophageal adenocarcinoma, colon cancer and pancreatic cancer.⁷⁸–⁸⁵

In conclusion, there is a growing body of evidence that pinpoint aminopeptidase activity, especially APN and ERAP1/2, to a great variety of cancer types and their progressive and proliferative state.

2. Mechanism of action of aminopeptidase inhibitors

The first clinically approved aminopeptidase inhibitor bestatin (Ubenimex), discovered by Umezawa et al., was originally designed as an immune-modulating agent.³ Follow up research demonstrated that bestatin also harbored antiproliferative effects and displayed activity as an anti-cancer drug, corroborating the relevance of aminopeptidases in cancer tissue.¹,²,⁸⁶,⁸⁷ As a mechanism of action, Taylor revealed that bestatin was tightly bound to the aminopeptidases LAP and APN.⁴ Each subunit of LAP was capable of bestatin binding, but the binding of one bestatin molecule was already sufficient to exert an inhibitory effect. Additionally, Botbol and Scornik noted that bestatin induced the accumulation of di- and tripeptide intermediates, again indicating aminopeptidase inhibition as a mechanism of action.⁸⁸ Almost two decades later, Krige et al. provided evidence that for the aminopeptidase inhibitor prodrug tosedostat (CHR2797), its main mechanism of action was to provoke a depletion of intracellular amino acids, which suppressed cell growth.⁹⁹ Consistent with earlier studies, also tosedostat exposure introduced intracellular accumulation of small peptides. Intracellular amino acid depletion triggers the so-called amino acid deprivation response (AADR), which is involved in transcriptional and post-transcriptional regulatory mechanisms, such as upregulation of amino acid synthetic genes, amino acid transporters, and tRNA synthetases (Figure 2). Lastly, Krige et al. observed that aminopeptidase inhibition reduced the phosphorylation of mammalian target of rapamycin (mTOR) substrates to suppress rates of protein synthesis.⁸⁹ mTOR is a protein kinase known as the master regulator of protein synthesis, cell growth and proliferation.⁹⁰ The mTOR protein exists of two distinct multi-protein complexes; mTOR complex
1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 stimulates protein synthesis by phosphorylating the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and the p70 ribosomal 6S kinase 1 (S6K1). Phosphorylation of 4E-BP1 prevents its binding to eukaryotic initiation factor 4E (eIF4E), enabling eIF4E to promote cap-dependent translation. The induction of S6K1 activity by mTORC1 leads to an increase in mRNA biogenesis, cap-dependent translation and elongation, and the translation of ribosomal proteins through regulation of the activity of many proteins. Amino acids can strongly regulate mTORC1 activity, but the mechanism by which intracellular amino acids signal to mTORC1 is still largely unresolved. Recent evidence suggested that the amino acid leucine is essential for mTORC1 activation, levels of which rely on transport into cells in a glutamine-dependent fashion. Next, the Rag proteins, a family of four related small GTPases, also interact with mTORC1 in an amino acid-sensitive manner and are also necessary for the activation of the mTORC1 pathway. In contrast

---

**Figure. 2. Mechanism of action of aminopeptidase inhibitors bestatin and tosedostat.**

*Aminopeptidase inhibitors elicits two main effects: 1) amino acid deprivation response (AADR) and 2) inhibition of mTOR. Modified from: Löwenberg et al. 2010.*
to mTORC1, mTORC2 activity is less directly affected by amino acid depletion, though through facilitating phosphorylation of Akt, it can promote mTORC1 activity as a compensatory mechanism. As such, mTORC2 plays key roles in cell survival, metabolism, proliferation and cytoskeleton organization.\textsuperscript{91,93,94} Collectively, aminopeptidase inhibitors elicit their effect mainly by induction of AADR and reduction of mTOR activity, which ultimately results in the inhibition of cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.\textsuperscript{90,95,96} This unique mechanism of action merits further clinical exploitation and implementation in current cancer chemotherapy.

3. Aminopeptidase inhibitors in cancer therapy
Currently, neither the European Medicines Agency (EMA) nor the Food and Drug Administration (FDA) have approved any aminopeptidase inhibitor in an anticancer treatment setting. However, some clinical trials are ongoing or completed, being most advanced for bestatin (Ubenimex) and tosedostat (CHR2797). Whereas bestatin is a direct aminopeptidase inhibitor, tosedostat is a hydrophobic aminopeptidase inhibitor prodrug that is rapidly taken up by cells and then intracellular activated by de-esterification into a hydrophilic pharmacologically active acid product (CHR79888). This hydrophilic metabolite is efficiently retained in cells to exert an inhibitory effect to multiple aminopeptidases, with preference for LTA\textsubscript{4} hydrolase, APN and LAP.\textsuperscript{89} Below, different aminopeptidases will be discussed in the context of clinical cancer therapy and the development of next generation experimental aminopeptidase inhibitors.

3.1 Aminopeptidase inhibitors tested in the clinic
Bestatin was used in Japan as an immunomodulator and antitumor drug (lung cancer and acute myeloid leukemia), under the trademark Ubenimex (Nippon Kayaku Co, Tokyo).\textsuperscript{86} Its broader clinical development proceeds at a low scale. The outcome of recent clinical studies in solid tumors and leukemia with single agent bestatin and tosedostat are shown in Table 1.

3.2 New compounds in development
There are two main approaches for aminopeptidase targeting; by direct inhibition or via prodrugs, which are enzymatically metabolized into a pharmacologically
Table 1. Overview clinical studies with aminopeptidase inhibitors bestatin and tosedostat.

<table>
<thead>
<tr>
<th>Phase</th>
<th>n</th>
<th>Cohort</th>
<th>Age [years]</th>
<th>Design/ Schedule</th>
<th>Activity</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>40</td>
<td>Advanced solid tumor</td>
<td>24-80</td>
<td>10 mg (oral) tosedostat daily for 7, 14, 21 or 28 days (increased duration study). 10-320 mg (oral) tosedostat daily for 28 days (dose escalation study)</td>
<td>Most commonly observed toxicities: fatigue, diarrhea, peripheral edema, nausea, dizziness, and constipation. 1 patient had partial response (renal cell carcinoma) and 4 patients had stable disease (&gt;6 months). Acceptable safe dose is 240 mg/day.</td>
<td>111</td>
</tr>
<tr>
<td>I</td>
<td>16</td>
<td>Elderly and/or relapsing/refractory patients with AML or MDS or MM</td>
<td>45-84</td>
<td>60-180 mg (oral) tosedostat daily for 84 days (MTD determined during first 28 days)</td>
<td>Most commonly reported severe adverse event was reduction in the platelet count (56%). 130 mg tosedostat is well tolerated.</td>
<td>96</td>
</tr>
<tr>
<td>II</td>
<td>41</td>
<td>Elderly and/or relapsing/refractory patients with AML or MDS or MM</td>
<td>34-82</td>
<td>130 mg (oral) tosedostat daily for 84 days</td>
<td>Objective response rate of 27% (age &gt; 60 years) and 79% had relapsed/refractory AML. The median duration of responses was 95 days (range 28-478 days). Tosedostat has significant antileukemic activity.</td>
<td>96</td>
</tr>
<tr>
<td>III</td>
<td>400</td>
<td>Resected stage I squamous-cell carcinoma</td>
<td>41-76</td>
<td>30 mg (oral) bestatin or placebo daily for 2 years (adjuvant therapy)</td>
<td>5-year survival rate was 81.0% of bestatin group and 74.2% of placebo group. 5-year disease free survival rate was 71.6% of bestatin group and 62.0% of placebo group. Postoperative adjuvant setting yields a significant improvement.</td>
<td>105</td>
</tr>
</tbody>
</table>

Abbreviations; f.i.m.: first-in-man, P.R.: prospective randomized, AML: acute myeloid leukemia, MDS: high-risk myelodysplastic syndrome, MM: multiple myeloma, MTD: maximum tolerated dose.

active acid products. In order to improve on selectivity, pharmacokinetics/dynamics, most rationally designed novel aminopeptidase inhibitors build on bestatin as prototypical compound. Remarkably, most of newly generated compounds came out as inhibitors of APN rather than of other aminopeptidases. A selection of recently identified experimental aminopeptidase inhibitors; their chemical structure and activity profile is listed in Table 2.
### TABLE 2. New compounds in development with aminopeptidase inhibitor function.

<table>
<thead>
<tr>
<th>Aminopeptidase Inhibitor</th>
<th>Structure</th>
<th>Drug approach</th>
<th>Structure based on</th>
<th>Activity (Ref)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tosedostat (CHR-2797)</td>
<td><img src="image1" alt="Structure" /></td>
<td>Prodrug</td>
<td>Batimastat (BB-94)</td>
<td>Anti-proliferative effects against a range of tumor cell lines in vitro and in vivo. Selectivity for transformed over non-transformed cells, anti-proliferative effects are much more potent than bestatin. (89)</td>
</tr>
<tr>
<td>LYP</td>
<td><img src="image2" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>Bestatin</td>
<td>Greater inhibitory effect of LYP compared to bestatin at same concentrations in different human ovarian carcinoma cell lines and xenograft mouse models. (104)</td>
</tr>
<tr>
<td>LYP3</td>
<td><img src="image3" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>Bestatin</td>
<td>LYP3 better water-soluble and much higher inhibitory effect of APN compared to bestatin in multiple cell lines. (107)</td>
</tr>
<tr>
<td>3-amino-2-hydroxy-4-phenylbutanoylvalylleucine</td>
<td><img src="image4" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>Produced by the streptomyces strain HCCB10043</td>
<td>Greater activity than bestatin in an APN inhibition assay. Not yet been implicated in cancer therapy. (110)</td>
</tr>
<tr>
<td>Series of synthetic compounds targeting APN</td>
<td><img src="image5" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>D24</td>
<td>Three compounds 4m, 4t, and 4cc, exhibited most potent APN inhibitory activities and displayed significant anti-metastasis and anti-angiogenesis effects in vitro and in vivo, compared to bestatin. (112)</td>
</tr>
<tr>
<td>Series of amino acid ureido derivatives</td>
<td><img src="image6" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>Synthetic compounds designed by (112)</td>
<td>Most of amino acid ureido derivatives exhibited good inhibition against APN, several better than bestatin. Most active compound, 12j, exhibited significant inhibitory effect of human cancer cell invasion. (113)</td>
</tr>
<tr>
<td>Novel lead structures as potent APN inhibitors</td>
<td><img src="image7" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>Virtual screening of commercial database containing about 160,000 molecules</td>
<td>24 molecules were selected for enzyme inhibition assay. Compound 2 exhibited highest inhibitory effect and good anti-proliferative activity against broad spectrum of human cancer cell lines. It induced cell cycle arrest at G1 phase and eventual apoptosis. (103)</td>
</tr>
<tr>
<td>CIP-13F</td>
<td><img src="image8" alt="Structure" /></td>
<td>Direct inhibitor</td>
<td>X-ray structure of APN/CD13 and structure bestatin</td>
<td>CIP-13F treatment resulted in a significant delay of Lewis lung carcinoma (LLC) growth, decrease in number of pulmonary metastasis and induction of LLC apoptosis. CIP-13F caused decreases in microvessel density (MVD) and angiogenic factors (109).</td>
</tr>
</tbody>
</table>
3.3 Aminopeptidase inhibitory profiles of classical and novel experimental aminopeptidase inhibitors

Following medicinal chemistry, preclinical evaluation of classical and novel experimental aminopeptidase inhibitors includes assessment of their inhibitory potency against one or multiple crude/purified aminopeptidases from human and rodent sources. Table 3 provides an overview of inhibitory potency of bestatin, tosedostat and selected novel aminopeptidase inhibitors against APN (most commonly tested), LAP, PuSA, LTA₄-hydrolase and ERAP1. With bestatin and tosedostat/CHR79888 as a reference, displaying potent inhibitory effects against APN, LAP, LTA₄ hydrolase and PuSA, most novel inhibitors displayed APN inhibitory capacity, with the 4cc compound being more potent that bestatin and tosedostat. Overall, natural inhibitors showed lower toxicity, broad spectrum activity and poor tissue specificity as compared to synthetic inhibitors. It remains a challenge to design inhibitors that could selectively target specific aminopeptidases, which can be implicated in cancer or chronic inflammatory diseases (e.g. LTA₄ hydrolase).

4. Resistance modalities for aminopeptidase inhibitors

Prolonged drug administration often comes along with the onset of acquired drug resistance. Also for aminopeptidase inhibitors, therapy resistance may occur as observed in a phase I/II clinical studies with tosedostat. However, the molecular basis for resistance remains elusive. Some mechanisms that may confer resistance are briefly discussed below just as options to overcome resistance.

4.1 Possible mechanisms of resistance

One general mechanism of drug resistance relates to cellular extrusion of drugs, mediated by ATP-dependent drug efflux pumps. In fact Grujic et al., showed that inhibition of multidrug resistance-associated protein (MRP) and P-glycoprotein (P-gp) enhanced the activity of both bestatin and actinonin, suggesting that these compounds may be substrates for these efflux pumps. Additionally, activation of mTOR by free amino acids can induce resistance as part of overcoming the amino acid deprivation response. These amino acids may be delivered through upregulated expression of amino acid transporters.
Table 3. IC50 (nmol/L) values of aminopeptidase inhibitors involved in cancer therapy for five different targets

<table>
<thead>
<tr>
<th>Aminopeptidase Inhibitor</th>
<th>Structure</th>
<th>APN</th>
<th>LAP</th>
<th>PuSa</th>
<th>LTA4 hydro-lase</th>
<th>ERAP1</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bestatin</td>
<td><img src="image" alt="Structure" /></td>
<td>300</td>
<td>4</td>
<td>350</td>
<td>200</td>
<td>&gt;5,000</td>
<td>89</td>
</tr>
<tr>
<td>Tosedostat (CHR-2797)</td>
<td><img src="image" alt="Structure" /></td>
<td>220</td>
<td>100</td>
<td>150</td>
<td>&gt;10,000</td>
<td>&gt;5,000</td>
<td>89</td>
</tr>
<tr>
<td>CHR-79888</td>
<td><img src="image" alt="Structure" /></td>
<td>190</td>
<td>30</td>
<td>850</td>
<td>8</td>
<td>&gt;5,000</td>
<td>89</td>
</tr>
<tr>
<td>Actinonin</td>
<td><img src="image" alt="Structure" /></td>
<td>160-5000</td>
<td>860-1190</td>
<td></td>
<td></td>
<td></td>
<td>116, 98</td>
</tr>
<tr>
<td>Amastatin</td>
<td><img src="image" alt="Structure" /></td>
<td>980</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>102, 108</td>
</tr>
<tr>
<td>Amino acid ureido derivate (12j)</td>
<td><img src="image" alt="Structure" /></td>
<td>1,100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>113</td>
</tr>
<tr>
<td>AG-205/36450018</td>
<td><img src="image" alt="Structure" /></td>
<td>3,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>103</td>
</tr>
<tr>
<td>PAQ-22</td>
<td><img src="image" alt="Structure" /></td>
<td>&gt;100,000</td>
<td>3800</td>
<td></td>
<td></td>
<td></td>
<td>106</td>
</tr>
<tr>
<td>PAQ-22/36c</td>
<td><img src="image" alt="Structure" /></td>
<td>&gt;100,000</td>
<td>500</td>
<td></td>
<td></td>
<td></td>
<td>106</td>
</tr>
<tr>
<td>LYP3</td>
<td><img src="image" alt="Structure" /></td>
<td>7,200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>107</td>
</tr>
<tr>
<td>4cc</td>
<td><img src="image" alt="Structure" /></td>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>112</td>
</tr>
</tbody>
</table>

Consistently, Fan et al.\textsuperscript{99} showed that L-amino acid transporter (LAT1) was upregulated in human ovarian cancer cells and that the inhibition of LAT1 sensitized cells for bestatin. Conceivably, for aminopeptidase inhibitor prodrugs like tosedostat, it may be anticipated that down-regulation of carboxylesterases,
implicated in the conversion of tosedostat to the active metabolite CHR79888, could be a contributing factor in loss of activity of tosedostat. These mechanisms warrant further exploration and confirmation in preclinical model systems and in a clinical setting.

4.2 Combination therapy to bypass resistance
Personalized medicine has received considerable attention in current cancer chemotherapeutic approaches. Aminopeptidase inhibitors can either be used in combination with other drugs to enhance their own activity and reduce toxicity, or could constitute synergistic interactions with other chemotherapeutic or therapies. Table 4 depicts an overview of completed and ongoing clinical studies of combination therapies with aminopeptidase inhibitors. As an example, showed that the combination of bestatin and a LAT1 inhibitor significantly increased bestatin activity in human ovarian cancer cells, which may thus be considered as an improved treatment option for ovarian cancer patients. demonstrated that inhibition of APN by Ubenimex enhanced radiosensitivity of cervical cancer cells in vitro as well as in vivo (mouse models). In the clinical setting tosedostat is combined with standard chemotherapy regimens in order to determine whether this would improve their efficacy. Moreover, inhibition of aminopeptidases leading to amino acid deprivation has a clear scientific rationale for these combinations. E.g. for the synthesis of RNA and DNA precursors amino acids are essential, so that combination with antimetabolites, such as with cytarabine in AML is likely to be beneficial. Moreover, inhibition of either aminopeptidases or the proteasome will prevent degradation of enzymes involved in DNA repair, apoptosis and signaling. Therefore interaction with drugs such as anthracyclines, also used in the treatment of AML are likely to be synergistic. All these options need further investigations. Together, the unique mechanism of action of aminopeptidase inhibitors has attractive options to further explore synergistic drug/therapeutic combinations.

CONCLUDING REMARKS
A growing body of data has underscored the critical role of aminopeptidases in various types of cancer tissues. One role involves protein/peptidase degradation
### TABLE 4. Clinical studies of approved cancer therapies combined with aminopeptidase inhibitors

<table>
<thead>
<tr>
<th>Phase</th>
<th>n</th>
<th>Cohort</th>
<th>Age (years)</th>
<th>Design/ Schedule</th>
<th>Activity(Ref.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.R.</td>
<td>242</td>
<td>AML &amp; complete remission</td>
<td>65-80</td>
<td>200 mg/m2 (iv) BHAC daily (combined with several other cancer therapeutics) with or without 30 mg ubenimex daily</td>
<td>Ubenimex group showed marginal benefit in RFS and no improvement of OS (115)</td>
</tr>
<tr>
<td>Ib</td>
<td>23</td>
<td>Advanced/ refractory solid tumors</td>
<td>&gt;18</td>
<td>135–175mg m2 (iv) paclitaxel once every 3 weeks for 6 cycles combined with 90–240 mg tosedostat daily</td>
<td>Combination is well tolerated. 3 patients had partial response, 12 patients stable disease (&gt;3 months) (114)</td>
</tr>
<tr>
<td>II</td>
<td>60</td>
<td>AML or MDS</td>
<td>&gt;18</td>
<td>Cytarabine or decitabine daily (5 days) combined with tosedostat daily (21 days)</td>
<td>Ongoing (NCT01567059)</td>
</tr>
<tr>
<td>I/II</td>
<td>96</td>
<td>AML or MDS</td>
<td>&gt;18</td>
<td>Cytarabine or 5-azacitidine daily (5 days) combined with tosedostat daily (21 days)</td>
<td>Ongoing (NCT01636609)</td>
</tr>
<tr>
<td>II</td>
<td>253</td>
<td>AML</td>
<td>&gt;18</td>
<td>45 mg/m2 (iv)</td>
<td>Ongoing (Hovon103)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AML or RAEB</td>
<td>&gt;66</td>
<td>daunorubicin daily 3 days) with 200 mg/m2 (iv) cytarabine daily (7 days) and assigned dose of tosedostat (oral) daily (21 days)</td>
<td></td>
</tr>
</tbody>
</table>


to free amino acid which is required for renewed protein biosynthesis, while the other role involves trimming of antigenic peptides for MHC class I presentation. Although aminopeptidases represent attractive candidates for therapeutic intervention, development of aminopeptidase inhibitors is in a relatively early stage, compared to the development of inhibitors of the proteasome, which functions upstream of aminopeptidases in protein degradation. This may be related to the broad spectrum of functions regulated by individual aminopeptidases preventing a specific inhibition. Moreover aminopeptidase...
inhibition may affect various physiological processes (e.g. cell adhesion, enzymatic regulation of peptides, differentiation, proliferation, chemotaxis, antigen presentation, cholesterol metabolism, phagocytosis and angiogenesis). However, in a cancer therapeutic setting, two of the most advanced studied aminopeptidase inhibitors (i.e. bestatin and tosedostat) were generally well tolerated with most of the patients only experiencing mild adverse events (grade 1-2). Another unresolved issue relates to the fact that aminopeptidases have a broad and overlapping substrate specificity, and therefore inhibition may not always be specific. It is a challenge for medicinal chemists to rationally design selective inhibitors for individual aminopeptidases and explore whether this could elicit differential effects against specific types of cancer, or even non-malignant diseases (e.g. HIV, malaria, Alzheimer disease, chronic inflammatory diseases). Expanded knowledge of the mechanism of action and putative resistance modalities may also help to define optimal application of aminopeptidase inhibitors in future cancer chemotherapy. Lessons learned from (pre)clinical investigations with tosedostat highlighted the impact of the amino acid depletion and inability to deal with the associated amino acid deprivation response as a critical factor in suppressing cancer cell growth. Hence, promoting compensatory effects for amino acid depletion could dictate the efficacy of aminopeptidase inhibitors as stand-alone drugs. However, given their unique mechanism of action, it is anticipated that the most successful application will adhere to combinations with other chemotherapeutic drugs. As such, aminopeptidases and their inhibitors hold promise for future rationally designed chemotherapeutic applications.
References

170


171


172


173


174


175


176


177


178


179


180


181


182


183


184


185

Fruci D, Ferracuti S. Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and Leukemia/Lymphoma, carcinoma, and melanoma cell lines. J Immunol 2006;176:4869–79.

186


187


188


189


190


191


192


193


194


195